Gilead Sciences, Inc. (NASDAQ:GILD) is included among the The 15 Best Passive Income Stocks to Buy Right Now.
On November 12, Scotiabank analyst Louise Chen began covering ten large-cap biopharma companies and shared a “non-consensus” positive view on the sector, according to a report by The Fly. He noted that years of underperformance in large-cap biopharma stocks, compared to other sectors and major indices, could offer an attractive entry point ahead of the next wave of innovation, where companies will “treat to cure.” The company maintained its Outperform rating from Gilead Sciences, Inc. (NASDAQ:GILD).
Gilead Sciences, Inc. (NASDAQ:GILD) remains a reliable dividend payer. Its shares have risen more than 36% since the beginning of 2025, outperforming the broader market. Biotechnology continues to lead the HIV drug market, still driving most of its growth. In the third quarter, total revenue increased 3% year over year to reach $7.8 billion.
Gilead Sciences, Inc. (NASDAQ:GILD) has made progress in oncology in recent years, although the progress has not been without challenges. Oncology revenue fell 3% year over year to $78.8 million in the third quarter. Still, the company has a large and active oncology portfolio, which is now larger than its HIV portfolio. In the coming years, the company is expected to benefit from label expansions and new approvals in the cancer market, which should help increase overall sales.
While we recognize GILD’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 15 Extreme Dividend Stocks to Buy According to Hedge Funds and 15 Overlooked Dividend Stocks to Buy Right Now.
Disclosure: None.